Menu Search
Equities

Sedana Medical AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SEDANA:STO

Sedana Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)9.97
  • Today's Change0.03 / 0.30%
  • Shares traded109.26k
  • 1 Year change-45.34%
  • Beta1.2739
Data delayed at least 15 minutes, as of Feb 09 2026 17:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The one analyst offering a 12 month price target expects Sedana Medical AB (publ) share price to rise to 24.00 in the next year from the last price of 9.97.
High140.7%24.00
Med140.7%24.00
Low140.7%24.00

Dividends in SEK

Dividend information is not available for Sedana Medical AB (publ).
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)--
More ▼

Earnings history & estimates in SEK

On Oct 24, 2025, Sedana Medical AB (publ) reported 3rd quarter 2025 losses of -0.12 per share. This result exceeded the -0.13 consensus loss of the one analyst covering the company and exceeded last year's 3rd quarter results by 45.45%.
The next earnings announcement is expected on Feb 12, 2026.
Average growth rate+26.76%
Sedana Medical AB (publ) reported annual 2024 losses of -0.11 per share on Feb 13, 2025.
Average growth rate-6.71%
More ▼

Revenue history & estimates in SEK

Sedana Medical AB (publ) had 3rd quarter 2025 revenues of 41.21m. This missed the 45.00m estimate of the one analyst following the company. This was 15.60% below the prior year's 3rd quarter results.
Average growth rate+2.52%
Sedana Medical AB (publ) had revenues for the full year 2024 of 178.75m. This was 16.17% above the prior year's results.
Average growth rate+7.72%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.